Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vamorolone
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : Santhera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Santhera, Clinigen Sign Supply, Distribution Deal for AGAMREE® (Vamorolone)
Details : Under the agreement, Clinigen Group will supply and distribute Agamree (vamorolone) in countries where the product is not otherwise commercially available.
Product Name : Agamree
Product Type : Steroid
Upfront Cash : Undisclosed
January 06, 2025
Lead Product(s) : Vamorolone
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : Santhera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Clinigen Divests Global Rights to Four Cancer Support Therapies to CNX Therapeutics
Details : Under the terms of the divestment, Clinigen will divest four medicines, Cardioxane (dexrazoxane), Savene, Totect and Ethyol, all of which help mitigate the side effects patients may experience when treated with other cancer therapies, to CNX Therapeutics...
Product Name : Cardioxane
Product Type : Small molecule
Upfront Cash : Undisclosed
August 10, 2023
Lead Product(s) : Dexrazoxane
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : CNX Therapeutics
Deal Size : Undisclosed
Deal Type : Divestment
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Iovance Biotherapeutics
Deal Size : $206.3 million
Deal Type : Divestment
Clinigen Divests Proleukin® to Iovance Biotherapeutics for £166.7 million
Details : Proleukin® (aldesleukin), a form of interleukin-2, is indicated for the treatment of adults with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC).
Product Name : Proleukin
Product Type : Large molecule
Upfront Cash : $206.3 million
January 23, 2023
Lead Product(s) : Aldesleukin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Iovance Biotherapeutics
Deal Size : $206.3 million
Deal Type : Divestment
Details : Orgovyx (relugolix), was granted approval by the European Medicines Agency (EMA) in April 2022 for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Product Name : Orgovyx
Product Type : Small molecule
Upfront Cash : Not Applicable
December 20, 2022
Lead Product(s) : Aldesleukin,Riluzole
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.
Product Name : Proleukin
Product Type : Large molecule
Upfront Cash : Not Applicable
December 08, 2022
Lead Product(s) : Aldesleukin,Riluzole
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lenzilumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Humanigen
Deal Size : Not Applicable
Deal Type : Not Applicable
Humanigen Launches Managed Access Program for Lenzilumab
Details : Humaneered (lenzilumab), is an investigational product that is not currently authorized or approved in any country, now available for certain hospitalized COVID-19 patients through its newly-launched LenzMAP.
Product Name : Humaneered
Product Type : Large molecule
Upfront Cash : Not Applicable
February 09, 2022
Lead Product(s) : Lenzilumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Humanigen
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Totect® now can be used for reducing the incidence and severity of cardiomyopathy associated with doxorubicin in women with breast cancer who have received a cumulative doxorubicin dose of 300 mg/m² and who will continue to receive doxorubicin therapy.
Product Name : Totect
Product Type : Small molecule
Upfront Cash : Not Applicable
November 10, 2020
Lead Product(s) : Dexrazoxane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Agreement
Details : The collaboration will be working to progress SNG001 through the required clinical and regulatory channels to make this potentially critical treatment widely available to COVID-19 patients around the world.
Product Name : SNG001
Product Type : Large molecule
Upfront Cash : Undisclosed
September 29, 2020
Lead Product(s) : Interferon Beta-1A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Synairgen
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Aldesleukin
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinigen's ALS Therapy Bags US Orphan Status
Details : According to the firm, the ODD recognises the potential therapeutic role of aldesleukin in treating disease, and could provide a number of benefits for Clinigen should it obtain a marketing approval for this indication.
Product Name : Proleukin
Product Type : Large molecule
Upfront Cash : Not Applicable
July 13, 2020
Lead Product(s) : Aldesleukin
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Interleukin 2,Tumor infiltrating lymphocyte,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Clinigen Demonstrates IL-2 Plays Role in Emerging TIL Therapies
Details : Study aimed at evaluating the safety and efficacy of TIL therapy in metastatic NSCLC (mNSCLC) after evidence of progression on nivolumab.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Not Applicable
May 04, 2020
Lead Product(s) : Interleukin 2,Tumor infiltrating lymphocyte,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable